With the goal of improving the lives of people affected by cancer, oncology research at Bayer is working on developing new cancer treatments and making them available to patients who need them all over the world. Our pipeline explores specific treatment approaches for various tumors, including such common types of cancer as prostate, lung and breast cancer, as well as rarer forms like kidney, liver and thyroid cancer.
A key starting point in oncology research at Bayer is identifying suitable molecular targets at different stages of tumor evolution with the aim of killing tumor cells and stopping tumor growth. Novel therapeutic strategies can then be derived from such targets. For example, kinase inhibitors are a class of active ingredients that has emerged from this research. Bayer's target-discovery efforts focus particularly on the cell cycle, survival signaling, immunotherapy, antibody-drug conjugates, tumor metabolism and chromatin modulation.
Our own research activities are supported by numerous collaborations with national and international partners. Examples of such cooperation include the strategic partnership with the German Cancer Research Center and our collaboration with OncoMed Pharmaceuticals in the field of cancer stem cells. Our close networking among research experts encourages an open exchange of ideas and information and helps to realize our vision.
More information about our collaborations:
Learn more about the activities of our research focus: